Platelets >= ,/mm^, equivalent to CTCAE v . grade -
Bilirubin =< . x ULN (CTCAE v . grade )
Recovered to ? grade  NCI CTCAE version . from toxicity of prior chemotherapy or biologic therapy administered more than  weeks earlier.
Ongoing adverse effects from prior systemic treatment > NCI CTCAE Grade  (with the exception of Grade  alopecia)
Presence of ? CTCAE grade  toxicity (except alopecia and ototoxicity, which are excluded if ? CTCAE grade ) due to prior cancer therapy.
Ongoing infection > grade  NCI-CTCAE v.
Persistent proteinuria >= grade  NCI-CTCAE v.
Any Grade > (according to the NCI CTCAE .) adverse reaction unresolved from previous treatments and not readily managed and controlled with supportive care.
Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade  or  as per the NCI-CTCAE v ..
Non-manageable electrolyte imbalances including hypokalemia, hypocalcemia, or hypomagnesemia (Grade  or greater based on NCI-CTCAE v .).
Ongoing, clinically significant bleeding (CTCAE grade  or )
Significant recent bleeding history defined as NCI CTCAE grade ? within the last  months, unless precipitated by an inciting event (e.g., surgery, trauma, injury)
Ongoing infection > grade  NCI-CTCAE v.
Ongoing infection > grade  NCI-CTCAE version (v) .
Patients cannot have experienced a significant (CTCAE Grade  or  with or without neutropenia) infection within  weeks of their first dose of MT-.
Serum bilirubin less than or equal to . x ULN (CTCAE v. grade )
Subject has symptomatic cardiac disorders (CTCAE v. . Grade  and )
Afebrile (<C per CTCAE v.);
Patient has not recovered from toxicity from prior immune checkpoint inhibitor therapy. Recovery is defined as ? NCI-CTCAE Grade , except for liver function test levels which must be <Grade .
Afebrile (<C per CTCAE v.);
(Bevacizumab-related exclusion) Any previous venous thromboembolism > NCI CTCAE grade 
serum potassium NCI-CTCAE version . Grade <;
serum calcium NCI-CTCAE version . Grade <;
serum magnesium NCI-CTCAE version . Grade <;
Ongoing infection > grade  NCI-CTCAE v.
Subjects with baseline symptoms of fever and/or cough and/or shortness of breath and/or wheezing and/or fatigue grade >=  (CTCAE version [v].)
Patients with hypertriglyceridemia defined as > mg/dL (CTCAE Grade ).
Serum creatinine =< . X ULN (CTCAE grade  baseline)
Patients who have active clinically serious infection > CTCAE grade  are not eligible
Serum creatinine =< . x ULN (CTCAE grade  baseline)
Patients exhibiting baseline grade  or  by CTCAE criteria are excluded
Ongoing infection > Grade  NCI-CTCAE v .
Creatinine less than . x ULN (CTCAE Grade )
Bilirubin less than . x ULN (CTCAE Grade )
Bilirubin less than or equal to . x ULN (CTCAE v grade )
Serious uncontrolled infection > grade  (CTCAE v.)
Serious uncontrolled infection > grade  (CTCAE v.)
At least one clinical symptom probably or definitely attributed to KSHV-MCD\r\n* Intermittent or persistent fever for at least  week (>  Celsius degree [C])\r\n* Fatigue (Common Terminology Criteria for Adverse Events [CTCAE] grade  or greater)\r\n* Gastrointestinal symptoms (includes nausea and anorexia) (CTCAE grade  or greater)\r\n* Respiratory symptoms (includes cough and airway hyperreactivity) (CTCAE grade  or greater)
Clinical relevant AEs or laboratory results related to previous anti-neoplastic therapy have not resolved to a NCI-CTCAE grade ?.
Ongoing infection > grade  NCI-CTCAE v.
Recovery to baseline or ? Grade  CTCAE ver..
AST =< grade 
Patients with ataxia >= CTCAE grade  are ineligible
Grade - electrolyte abnormalities (CTCAE, v. ):
Triglycerides < CTCAE grade 
Magnesium >= within institutional normal limits, or =< grade  according to NCI-CTCAE version . if judged clinically not significant by the investigator
Subjects who have an active clinically serious infection of CTCAE grade >= 
Bilirubin less than or equal to . x ULN (CTEP CTCAE version ., grade )
Subject has any other organ dysfunction (CTCAE version . Grade ) that will interfere with the administration of the therapy according to this protocol.
Ongoing acute adverse effects from prior anticancer or investigational therapy > NCI CTCAE Grade 
Serum creatinine ? . X ULN (CTCAE Grade  baseline)
Ongoing clinical adverse events NCI CTCAE Grade > resulting from prior cancer therapies
Evidence of significant CNS haemorrhage i.e. CTCAE grade  or above;
All AEs resulting from prior chemotherapy, surgery, or radiotherapy, must have resolved to at least NCI-CTCAE (v. .) Grade  (except for laboratory parameters outlined below).
Ongoing infection > grade  NCI-CTCAE v .
Ongoing infection > Grade  NCI-CTCAE v..
Subjects with known Gilbert's syndrome who have serum bilirubin ?  x ULN (NCI CTCAE v. Grade ) may be enrolled.
Ongoing infection > grade  NCI-CTCAE v.
? CTCAE Grade  anemia, OR
? CTCAE Grade  hematoma (bleed)
Active infection > CTCAE Grade , that is considered clinically serious by the treating physician
Any Grade  or  toxicities (according to NCI CTCAE) resolved for at least  weeks prior to first treatment
CTCAE v. grade  or  anorexia or nausea related to metastatic disease.
Clinically significant bleeding NCI-CTCAE version . Grade  or higher within  days before randomization.
Bilirubin =< . x ULN, CTCAE grade 
EXPANSION COHORT ONLY: Resolution of any pre-existing toxicity from prior therapy to NCI CTCAE version . =< grade  except neuropathy (=< grade ) and tinnitus (=< grade ), and hearing loss (=< grade )
Any toxicity from prior chemotherapy has resolved or Grade  (NCI-CTCAE, Version .)
Ongoing infection > Grade  NCI-CTCAE v..
Subject has an ongoing toxicity ? Grade  (NCI CTCAE Version .) attributable to prior medication to treat solid tumor (except alopecia) at screening.
Active, clinically serious infections of NCI CTCAE v. Grade  or higher within  weeks prior to Cycle , Day 
Subject has an ongoing toxicity greater than or equal to grade  (NCI CTCAE version .) attributable to prior NSCLC treatment at the time of screening.
Bilirubin less than or equal to . x ULN (CTCAE v. grade )
Ongoing infection > grade  NCI-CTCAE v.
Anxiety ? CTCAE grade 
Patients with active clinically serious infections defined as >= grade  according to NCI CTCAE, version .
Subjects with valvular heart disease CTCAE (version .) grade 
? CTCAE Grade  anxiety.
Diarrhoea CTCAE v. Grade ? 
Evidence of uncontrolled bradycardia or other cardiac arrhythmia defined as ?Grade  according to NCI CTCAE, version ., or uncontrolled hypertension
History of bronchopulmonary hemorrhage NCI CTCAE >/= Grade  within  months prior to randomization
NCI CTCAE (version .) Grade  or higher toxicities due to prior therapy that have not shown improvement and are considered to interfere with current study medication
Active clinically serious infections defined as >= Grade  according to NCI CTCAE
CTCAE Grade  or  fatigue.
Any >=Grade  hypophosphatemia (per CTCAE v.) at the time of enrolment
Active clinically serious infection > NCI-CTCAE grade 
? CTCAE grade  anxiety
Active clinically serious infection > CTCAE v . grade 
Active clinically serious infections > Grade  (NCI-CTCAE Version .)
Ongoing infection > CTCAE grade 
Baseline alopecia (defined CTCAE v. grade > )
Ongoing infection > grade  NCI-CTCAE v.
History of persistent proteinuria >= grade  NCI-CTCAE v.
AST > . x ULN (CTCAE grade )
Bilirubin > . x ULN (CTCAE grade )
Current alopecia grade  or greater as per NCI-CTCAE v.., or significant hair loss or hair breakage
Hepatic toxicity >= grade  (using CTCAE version  standard definitions)
Not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE Grade <= or baseline.
For Adjuvant Treatment: All AEs resulting from surgery must have resolved to NCI-CTCAE (v. .) Grade ? 
